Triterpene derivatives as inhibitors of protein involved in the inflammatory process: Molecules interfering with phospholipase A2, cycloxygenase, and lipoxygenase

Current Drug Targets

Volumn 12, Issue 3, 2011, Pages 302-321

  Braca, Alessandra ^a   Dal Piaz, Fabrizio ^b   Marzocco, Stefania ^b   Autore, Giuseppina ^b   Vassallo, Antonio ^b   de Tommasi, Nunziatina ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

Anti inflammatory; Cycloxygenase; Lipoxygenase; Phospholipase a2; Triterpene derivatives

Indexed keywords

4 METHOXYCINNAMOYL OLEANANE; ALPHA AMYRIN; AVICIN G; BETA AMYRIN; BETULIC ACID; BOSWELLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 3; DEHYDROTUMULOSIC ACID; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; MASTICADIENONIC ACID; OLEANOLIC ACID; PACHYMIC ACID; PENASTEROL; PENASTERONE; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PLATYCODIN; PRISTIMERIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; SCHINOL; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSOLIC ACID; ZANHASAPONIN A; ZANHASAPONIN B; ZANHASAPONIN C;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG STRUCTURE; ENZYME INHIBITION; INFLAMMATION; NONHUMAN;

EID: 79551630308     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945011794815284     Document Type: Article

References (110)

1. Nathan C. Points of control in inflammation. Nature 2002; 420: 846-52.
2. Barton GM. A calculated response: control of inflammation by the innate immune system. J Clin Invest 2008; 118: 413-20.
3. Addad F, Lafont A, Gamra H, et al. Coronary angioplasty in the acute phase of a myocardial infarction on a myocardial bridge. Can J Cardiol 2005; 21: 1183-5.
4. Mantovani A, Pierotti MA. Cancer and inflammation: a compelx relationship. Cancer Lett 2008; 267: 180-1.
5. Lawrence T. Inflammation and cancer: a failure of resolution? Trends Pharmacol Sci 2007; 28: 162-5.
6. Burke A, Smith E, FitzGerald GA. Analgesic-Antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics; Brunton L, Lazo J, Parker K, Buxton I, Blumenthal D, eds. New York: McGraw-Hill 2006; 673-715.
7. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase - 2. N Engl J Med 2001; 345: 433-42.
8. Jachak SM. Cyclooxygenase inhibitory natural products: current status. Curr Med Chem 2006; 13: 659-78.
9. 2. Jikken Igaku 2000; 18: 122-9.
10. Baker RR. The eicosanoids: a historical overview. Clin Biochem 1990; 23: 455-8.
11. Smith WL, Dewitt DL. Cyclo-oxygenase inhibitors. Ther Immunol 1996; 119-31.
12. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41: 661-90.
13. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294: 1871-5.
14. Dannhardt G, Kiefer W. Cyclooxygenase inhibitors - current status and future prospects. Eur J Med Chem 2001; 36: 109-26.
15. Tanabe T, Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 2002; 68: 95-114.
16. 2. Prostaglandins Leukot Essent Fatty Acids 2003; 69: 87-97.
17. Cook JA. Eicosanoids. Crit Care Med 2005; 33: S488-91.
18. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 2004; 103: 147-66.
19. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99: 13926-31.
20. Süleyman H, Demircan B, Karagöz Y, Oztaşan N, Süleyman B. Anti-inflammatory effects of selective COX-2 inhibitors. Pol J Pharmacol 2004; 56: 775-80.
21. Simmons DL. Variants of cyclooxygenase-1 and their roles in medicine. Thromb Res 2003 15;110: 265-8.
22. Bürger F, Krieg P, Marks F, Fürstenberger G. Positionaland stereoselectivity of fatty acid oxygenation catalysed by mouse 12(S)-lipoxygenase isoenzymes. Biochem J 2000; 348: 329-35.
23. Sun D, McDonnell M, Chen XS, et al. Human 12(R)-lipoxygenase and the mouse ortholog. J Biol Chem 1998; 273: 33540-7.
24. Schneider I, Bucar F. Lipoxygenase inhibitors from natural plant sources. Part 1: Medicinal plants with inhibitory activity on arachidonate 5-lipoxygenase and 5-lipoxygenase/cyclooxygenase. Phytother Res 2005; 19: 81-102.
25. Polya G. Biochemical Targets of Plant Bioactive Compounds. London: Taylor & Francis 2003.
26. Folco G, Murphy RC. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol Rev 2006; 58: 375-88.
27. Werz O, Steinhilber D. Therapeutic options for 5-LOX inhibitors. Pharmacol Ther 2006; 112: 701-18.
28. Yoshimoto T, Takahashi Y. Arachidonate 12-lipoxygenases. Prostaglandins Other Lipid Mediat 2002; 68: 245-62.
29. Nie D, Honn KV. Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cell Mol Life Sci 2002; 59: 799-807.
30. Nie D, Che M, Grignon D, Tang K, Honn KV. Role of eicosanoids in prostate cancer progression. Cancer Metastasis Rev 2001; 20: 195-206.
31. Müller K, Altmann R, Prinz H. 2-Arylalkyl-substituted anthracenones as inhibitors of 12-lipoxygenase enzymes. 2. Structure-activity relationships of the linker chain. Eur J Med Chem 2002; 37: 83-9.
32. Müller K. 5-Lipoxygenase and 12-lipoxygenase: Attractive targets for the development of novel antipsoriatic drugs. Arch Pharm 1994; 327: 3-19.
33. Cornicelli JA, Triveti BK. 15-LOX and its inhibition: a novel therapeutic target for vascular disease. Curr Pharm Des 1999; 5: 11-20.
34. Jachak SM, Saklani A. Challenges and oppurtunities in drug discovery from plants. Curr Sci 2007; 92: 1251-7.
35. Boldi AM. Libraries from Natural product-like scaffolds. Curr Opin Chem Biol 2004; 8: 281-6.
36. Newmann DJ, Cragg GM, Snader KM. Natural Products as source of new drug over the last 25 years. J Nat Prod 2007; 70: 461-7.
37. Breinbauer R, Vetter IR, Waldmann H. From protein domains to drug candidates-Natural Products as Guiding Principles in the Design and Synthesis of Compound Libraries. Angew Chem Int Ed Engl 2002; 41: 2878-90.
38. Haralampidis K, Trojanowska M, Osbourn AE. Biosynthesis of triterpenoid saponins in plants. Adv Biochem Eng Biotechnol 2002; 75: 31-49.
39. Kuo R, Quian K, Morris-Natschke SL, Lee K. Plant-derived triterpenoids and analogues as antitumor and anti-HIV agents. Nat Prod Rep 2009; 26: 1321-44.
40. Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Med 2006; 72: 1100-16.
41. Liby K, Honda T, Williams CR, et al. Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities. Mol Cancer Ther 2007; 6: 2113-9.
42. Giner-Larza EM, Manez S, Recio MC, Giner RM, Rios JL. A review on the pharmacology of lanostanes and related tetracyclic triterpenes. Res Adv Phytochemistry 2000; 1: 65-81.
43. 2 from berries of Schinus terebenthifolius. Phytochemistry 1995; 39: 537-47.
44. 2 in vesicles. Biochemistry 1991; 28: 4135-9.
45. 2: determination of the interfacial kinetic rate constants. Biochemistry 1991; 30: 7283-97.
46. 2 activity of extracts from lanostane-rich species. J Ethnopharmacol 2000; 73: 61-9.
47. Giner-Larza EM, Máñez S, Giner RM, et al. Anti-inflammatory triterpenes from Pistacia terebinthus galls. Planta Med 2002; 68: 311-5.
48. 2 inhibitors. J Nat Prod 1996; 59: 977-9.
49. 2 in vitro and in vivo by several novel series of inhibitor compounds. Biochem Pharmacol 1981; 30: 1315-24.
50. Giner EM, Manez S, Recio MC, Giner RM, Cerda-Nicolas M, Rios JL. In vivo studies on the anti-inflammatory activity of pachymic and dehydrotumulosic acids. Planta Med 2000; 66: 221-7.
51. Takei M, Umeyama A, Shoji N, Arihara S, Endo K. Mechanism of inhibition of IGE-dependent histamine release from rat mast cells by penasterol and penasterone. J Pharm Sci 1995; 84: 228-30.
52. 2 saponins from an antiinflammatory extract of Zanha africana root bark. J Nat Prod 1997; 60: 1158-60.
53. Ringbom T, Segura L, Noreen Y, Perera P, Bohlin L. Ursolic acid from Plantago major, a selective inhibitor of cyclooxygenase-2 catalyzed prostaglandin biosynthesis. J Nat Prod 1998; 61: 1212-5.
54. Suh N, Honda T, Finlay HJ, et al. Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages. Cancer Res 1998; 58: 717-23.
55. Suh N, Wang Y, Honda T, et al. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res 1999; 59: 336-41.
56. Subbaramaiah K, Michaluart P, Sporn MB, Dannenberg AJ. Ursolic acid inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Cancer Res 2000; 60: 2399-404.
57. Lee CH, Wu SL, Chen JC, et al. Eriobotrya japonica leaf and its triterpenes inhibited lipopolysaccharid-induced cytokines and inducible enzyme production via the nuclear factor κB signaling pathway in lung epithelial cells. Am J Chin Med 2008; 36: 1185-98.
58. Ishii H, Tori K, Yoshimura Y. Saponins from the roots of Platycodon grandiflorum. Part 1. Structure of prosapogenins. J Chem Soc Perkin Trans 1981; 11: 1928-33.
59. Tada A, Kaneiwa Y, Shoji J, Shibata S. Isolation and the structure of platycodin D. Chem Pharm Bull (Tokyo) 1975; 23: 2965-72.
60. Kim YP, Lee EB, Kim SY, et al. Inhibition of prostaglandin E2 production by platycodin D isolated from the root of Platycodon grandiflorum. Planta Med 2001; 67: 362-4.
61. Haridas V, Higuchi M, Jayatilake GS, et al. Avicins: triterpenoid saponins from Acacia victoriae (Bentham) induce apoptosis by mitochondrial perturbation. Proc Natl Acad Sci USA 2001; 98: 5821-6.
62. Haridas V, Arntzen CJ, Gutterman JU. Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), inhibit activation of NF-κB by inhibiting both its nuclear localization and ability to bind DNA. Proc Natl Acad Sci USA 2001; 98: 11557-62.
63. Pisha E, Chai H, Lee IS, et al. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1995; 1: 1046-51.
64. Evers M, Poujade C, Soler F, et al. Betulinic acid derivatives: a new class of human immunodeficiency virus type I specific inhibitors with a new mode of action. J Med Chem 1996; 39: 1056-68.
65. Mukherjee PK, Saha K, Das J, Pal M, Saha BP. Studies on the anti-inflammatory activity of rhizomes of Nelumbo nucifera. Planta Med 1997; 63: 367-8.
66. Takada Y, Aggarwal BB. Betulinic acid suppresses carcinogeninduced NF-κB activation through inhibition of IκBα kinase and p65 phosphorylation: abrogation of cyclooxygenase-2 and matrix metalloprotease-9. J Immunol 2003; 171: 3278-86.
67. Yun Y, Han S, Park E, et al. Immunomodulatory activity of betulinic acid by producing pro-inflammatory cytokines and activation of macrophages. Arch Pharm Res 2003; 26: 1087-95.
68. Otto JC, De Witt DL, Smith WL. N-glycosylation of prostaglandin endoperoxide synthase-1 and 2 an their orientations in the endoplasmic reticulum. J Biol Chem 1993; 68: 18234-42.
69. Kweifio-Okai G, de Munk F, Rumble BA, Macrides TA, Cropley M. Antiarthritic mechanisms of amyrin triterpenes. Res Commun Mol Pathol Pharmacol 1994; 85: 45-55.
70. Otuki MF, Vieira-Lima F, Malheiros A, Yunes RA, Calixto JB. Topical antiinflammatory effects of the ether extract from Protium kleinii and α-amyrin pentacyclic triterpene. Eur J Pharmacol 2005; 507: 253-9.
71. Medeiros R, Otuki MF, Avellar MCW, Calixto JB. Mechanisms underlying the inhibitory actions of the pentacyclic triterpene α-amyrin in the mouse skin inflammation induced by phorbol ester 12-O-tetradecanoylphorbol-13-acetate. Eur J Pharmacol 2007; 559: 227-35.
72. Vitor CE, Figueiredo CP, Hara DB, Bento AF, Mazzuco TL, Calixto JB. Therapheutic action and underlying mechanisms of a combination of two pentacyclic triterpenes, α- and β-amyrin, in a mouse model of colitis. Br J Pharmacol 2009; 157: 1034-44.
73. Lacaille-Dubois MA, Hanquet B, Cui ZH, Lou ZC, Wagner H. Acylated triterpene saponins from Silene jenisseensis. Phytochemistry 1995; 40: 509-14.
74. Siemoneit U, Hofmann B, Kather N, et al. Identification and functional analysis of cyclooxygenase-1 as a molecular target of boswellic acids. Biochem Pharmacol 2008; 75: 503-13.
75. Yoshikawa K, Inoue M, Matsumoto Y, et al. Lanostane triterpenoids and triterpene glycosides from the fruit body of Fomitopsis pinicola and their inhibitory activity against COX-1 and COX-2. J Nat Prod 2005; 68: 69-73.
76. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994; 47: 55-9.
77. Dirsch V, Wiemann W, Wagner H. Antiinflammatory activity of triterpene quinone-methides and proanthocyanidins from the stem bark of Heisteria pallida Engl. Pharm Pharmacol Lett 1992; 2: 184-6.
78. Wagner H, Wierer M, Bauer R. In vitro inhibition of prostaglandin biosynthesis by essential oils and phenolic compounds 1. Planta Med 1986; 52: 184-7.
79. Wagner H, Fessler B. In vitro 5-lipoxygenase inhibition by Eclipta alba extracts and the coumestan derivative wedelolactone. Planta Med 1986; 52: 374-7.
80. Shen YH, Weng ZY, Zhao QS, et al. Five new triterpene glycosides from Lysimachia foenum-graecum and evaluation of their effect on the arachidonic acid metabolizing enzyme. Planta Med 2005; 71: 770-5.
81. Mehdi HK, Ejaz A, Saira H, Abdul M, Itrat F, Muhammad A. Cashmirols A and B, new lipoxygenase inhibiting triterpenes from Sorbus cashmiriana. Chem Biodivers 2009; 6: 1471-6.
82. Kazmi MH, Ahmed E, Hameed S, Malik A, Ashrat M. Isolation and structural determination of sorbinols A and B, new triterpenes from Sorbus cashmariana, by 1D and 2D NMR spectroscopy. Magn Reson Chem 2007; 45: 416-9.
83. Tappel AL. Lipoxidase. In Methods in Enzymology; Colowick SP, Kaplan NO, Eds. New York: Academic Press 1962; Vol. 5: pp 539-42.
84. Sridhar C, Rao KV, Subbaraju GV. Flavonoids, triterpenoids and a lignin from Vitex altissima Phytochemistry 2005; 66: 1707-12.
85. Gay CA, Gebicki JM. Percloric acid enhances sensivity and reproducibility of the ferric-xylenol orange peroxide assay. Anal Biochem 2002; 304: 42-6.
86. Díaz AM, Abad MJ, Fernández L, et al. In vitro anti-inflammatory activity of iridoids and triterpenoid compound isolated from Phyllyrea latifolia L. Biol Pharm Bull 2000; 23:1307-13.
87. Safayhi H, Sailer ER, Ammon UPT. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-β-boswellic acid. Mol Pharmacol 1995; 47: 1212-6.
88. Kapil A, Sharma S. Effect of oleanolic acid on complement in adjuvant- and carrageenan-induced inflammation in rats. J Pharm Pharmacol 1995; 47: 585-7.
89. Bermejo Benito P, Abad Martinez MJ, Silan Sen AM, et al. In vivo and in vitro anti-inflammatory activity of saikosaponins. Life Sci 1998; 63: 1147-56.
90. Williams JD, Czop JK, Austem KF. Release of leukotrienes by human monocytes on stimulation of their phagocytic receptor for particulate activators. J Immunol 1984; 132: 3034-40.
91. Kweifio-Okai G, de Munk F, Macrides TA, Smith P, Rumble BA. Antiarthritic mechanisms of lupeol triterpenes Drug Dev Res 1995; 36: 20-4.
92. Rohmer M, Bouvier-Nave P, Ourisson G. Distribution of hopanoid triterpenes in prokaryotes. J Gen Microbiol 1984; 130: 1137-50.
93. Moreau RA, Agnew J, Hicks KB, Powell MJ. Modulation of lipoxygenase activity by bacterial hopanoids. J Nat Prod 1997; 60: 397-8.
94. Najid A, Simon A, Delage C, Chulia AJ, Rigaud M. A calluna vulgaris extract 5-lipoxygenaser inhibitor shows potent antiproliferative effects on human leukaemia HL60 cells. Eicosanoids 1992; 5: 45-51.
95. Es-Saady D, Najid A, Simon A, Denizot Y, Chulia AJ, Delage C. Effects of ursolic acid and its analogues on 15-lipoxygenase activity and the proliferation rate of a human gastric tumor cell line. Mediators Inflamm 1994; 3: 181-4.
96. Ammon HTP, Mack T, Singh GB, Safayhi H. Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudates of Boswellia serrata. Planta Med 1991; 57: 203-7.
97. Allan GG. The stereochemistry of the boswellic-acids. Phytochemistry 1968; 7: 963-73.
98. Belsner K, Büchele B, Werz U, Syrovets T, Simmet T. Structural analysis of pentacyclic triterpenes from the gum resin of Boswellia serrata by NMR spectroscopy. Magn Reson Chem 2003; 41: 115-22.
99. Khanna D, Sethi G, Ahn KS, et al. Natural products as a gold mine for arthritis treatment. Curr Opin Pharmacol 2007; 7: 344-51.
100. Poeckel D, Werz O. Boswellic acids: Biological actions and molecular targets. Curr Med Chem 2006; 13: 3359-69.
101. Kuhl P, Borbe H, Fischer H, Romer A, Safayhi H. Ebselen reduces the formation of LTB4 in human and porcine leukocytes by isomerization to its 5S,12R-6-trans-isomer. Prostaglandins 1986; 31: 1029-48.
102. Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, Ammon HPT. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 1992; 261: 1143-6.
103. Sailer ER, Subramanian LR, Rall B, Hoernlein RF, Ammon HPT, Safayhi H. Acetyl-11-keto-β-boswellic acid (AKBA): Structure requirements for binding and 5-lipoxygenase inhibitory activity. Br J Pharmacol 1996; 117: 615-8.
104. Sailer ER, Schweizer S, Boden SE, Ammon HPT, Safayhi H. Characterization of an acetyl-11-keto-β-boswellic acic and arachidonic-binding regulatory site of 5-lipoxygenase using photoaffinity labeling. Eur J Biochem 1998; 256: 364-8.
105. Poeckel D, Tausch L, Kather N, Jauch J, Werz O. Boswellic acid stimulated arachidonic acid release and 12-lipoxygenase activity in human platelets independent of Ca2+ and differentially interact with platelet-type 12-LO. Mol Pharmacol 2006; 70: 1071-8.
106. Siemoneit U, Pergola C, Jazzar B, et al. On the interference of boswellic acid with 5-lipoxygenase: mechanistic studies in vitro and pharmacological relevance. Eur J Pharmacol 2009; 606: 246-54.
107. Culioli G, Mathe C, Archier P, Vieillescazes C. A lupane triterpene from Frankinscence. Phytochemistry 2003; 62: 537-41.
108. Belsner K, Buchele B, Werz U, Syrovets T, Simmet T. Structural analysis of 3-α-acetyl 20(29)-lupene-24-oic acid, a novel pentacyclic triterpene isolated from the gum resin of Boswella serrata, by NMR spectroscopy. Magn Res Chem 2003; 41: 629-32.
109. Boden S E, Schweizer S, Bertsche T, Dufer M, Drews G, Safayhi H. Stimulation of leukotriene synthesis in intact polymorphonuclear cells by the 5-lipoxygenase inhibitor 3-oxotirucallic acid. Mol Pharmacol 2001; 60: 267-73.
110. Boden SE, Bertsche T, Ammon HPT, Safayhi H. MEK-1/2 inhibition prevent 5-LOX translocation in N-formylpeptidechallenged human neutrophils. Int J Biochem Cell Biol 2000; 32: 1069-74.